Nolvadex vs. Evista Breast Cancer Prevention Trial Proposed By NSABP
Executive Summary
A head-to-head comparative trial of Zeneca's Nolvadex (tamoxifen) and Lilly's Evista (raloxifene) in breast cancer prevention will be reviewed by the National Institutes of Health as a potential follow-up to the tamoxifen Breast Cancer Prevention Trial.